benecel™ ph dc hpmc
chemistry: cellulosics
SDS Link >To meet growing demand for Benecel™ PH DC hypromellose (hpmc), a patented, surface-modified, co-processed pharmaceutical excipient that provides improved performance in direct compression and continuous manufacturing controlled-release applications, Ashland has invested in additional, relocated manufacturing capacity.
While simultaneously reducing lead time to meet demand and improving delivery continuity, the investment also enhances Ashland’s production capacity for ancillary custom molecular weight Benecel™ hpmc pharmaceutical excipients. Customization of Benecel™ grades helps customers circumvent batch blending processes that can result in unpredictable release rate variability for active pharmaceutical ingredients (APIs).
applications
- tablet binding
- modified release
- continuous manufacturing
key features and benefits
Used for modified release and tablet binding, Benecel™ PH DC hpmc and related customizable forms deliver multiple benefits:
- improved powder flow
- increased predictability and reproducibility of drug release profiles
- identical, stable dissolution profiles compared with “CR” grades
- improved content uniformity
grades available
- benecel™ k4m ph dc hypromellose: 2,700 – 5,400 2% viscosity (mPas)
- benecel™ k15m ph dc hypromellose: 13,500 – 25,200 2% viscosity (mPas)
- benecel™ k100m ph dc hypromellose: 75,000 – 140,000 2% viscosity (mPas)
Read More >
additional content coming soon
additional content coming soon
additional content coming soon
additional content coming soon
related links
